Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

智通财经APP获悉，据外媒报道， 奥洛兹美医疗 (HALO.US)首席执行官海伦·托利 (Helen Torley)称，公司计划以现金形式融资20亿欧元 (合21亿美元)收购德国Evotec公司 ...

比特币从大选以来最大跌幅中反弹。 比特币价格波动加剧，从美国大选结果出炉以来最大的两天跌幅中反弹，反映出对当选总统特朗普政策议程影响的评估发生了变化。数据显示，比特币在上周六和上周日下跌了近3%。而截至发稿，比特币已涨至仅略低于9.2万美元的水平，但仍低于上周创下的约9.3万美元的历史新高。

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN ...

Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...

Buying Evotec would give Halozyme other revenue streams. Helen Torley, Halozyme’s CEO, explained the offer in a statement.

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...